在患有肌痛性脑筋炎/慢性疲劳综合征的患者中,皮里多斯提格改善了手握力
Ella Schlömer1, Elisa Stein1, Claudia Kedor1
1Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz, Berlin, Germany.
Frontiers in neuroscience
|September 19, 2025
概括
肌痛性脑筋炎/慢性疲劳综合征 (ME/CFS) 患者经历了改善的手握力和静止功能与pyridostigmine. 这种乙胆酶抑制剂显示出治疗ME/CFS症状的潜力.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌痛性脑筋炎/慢性疲劳综合征 (ME/CFS) 是一种复杂的多系统性疾病.
- 关键症状包括运动不耐受,疲劳,肌肉虚弱和疲劳.
- 作为一种乙胆酶抑制剂的pyridostigmine在改善ME/CFS患者心脏输出方面表现有前途.
研究的目的:
- 评估皮里多斯提格对ME/CFS患者手握强度的直接影响.
- 评估pyridostigmine对ME/CFS患者的正静功能的影响.
- 调查皮里多斯提格在治疗ME/CFS肌肉衰弱和疲劳方面的潜在作用.
主要方法:
- 20名患有后感染性ME/CFS的患者使用电动动力表进行了手握强度测试.
- 测量在1小时后重复测量,在初始测量后给出皮里多斯蒂格 (30毫克).
- 通过被动站立测试来评估静止功能;进行神经学检查和自身抗体测试以排除严重肌痛症.
主要成果:
- 患者表现出最大手握强度的降低,在皮里多斯蒂格明剂后,手握强度平均提高了2.6公斤.
- 运动后最大的手握强度显著高于 (1.5倍) 皮里多斯蒂格明 (p=0.01).
- 皮里多斯蒂格在静止测试期间降低了心率的增加 (p=0.017),表明静止功能得到改善.
结论:
- 在ME/CFS患者中,Pyridostigmine显示出对肌肉强度的立即积极影响.
- 该药物还可以增强静止功能,可能通过增加乙胆的可用性和副交感声调.
- 这些发现表明,pyridostigmine可能是ME/CFS症状的有益治疗选择.
相关概念视频
01:15Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
01:20Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
01:28Disorders of the Skeletal Muscle
1.7K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.7K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.5K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.5K
01:24Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
01:26Chemical Synapses
11.3K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
11.3K